Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Clinical Research
  • Published:

Physical activity decreases the risk of cancer reclassification in patients on active surveillance: a multicenter retrospective study

Prostate Cancer and Prostatic Diseases volume 24, pages 1151–1157 (2021)Cite this article

Subjects

Abstract

Background

Physical activity (PA) is associated with favorable outcomes in prostate cancer (PCa) patients. We assessed its effect on the risk of PCa reclassification (PCaR) during active surveillance.

Methods

Anthropometric, demographic, and clinical data concerning men diagnosed with a low-risk PCa and initially managed with active surveillance at the two participating institutions were retrospectively collected. The Physical Activity Scale for the Elderly (PASE) was used for patients’ self-assessment of their daily exercise and their consequent stratification into three groups: sedentary (PASE ≤ 65), moderately active (65 < PASE < 125), active (PASE ≥ 125). Kaplan–Meier model was used to evaluate the predictive role of PA on PCaR, computed at 2, 5, 10 years after diagnosis; differences between lifestyle groups were assessed using the log-rank and uni-/multivariable Cox analyses applied to identify predictors of reclassification.

Results

Eighty-five patients were included in the analysis, with a median age of 66 years (IQR: 59–70); 16% were active, 45% were former smokers, and 3 presented with metabolic syndrome (MetS). Prostate-specific antigen (PSA) density was 0.12 (IQR: 0.07–0.15); 34 men showed a PSA doubling time <10 years. The Median PASE score was 86 (IQR: 61.5–115.8): 24 patients were sedentary, 46 moderately active, and 15 active. At a median follow-up of 37 months (IQR: 14–53), 25% of patients experienced PCaR. These were less physically active (PASE score 69.3 vs 87.8; p = 0.056) and presented with significantly smaller prostates (46 ml vs 50.7 ml; p = 0.001) and a higher PSAD (0.14 vs 0.10; p = 0.019). At 2 years, the risk of reclassification was 25 ± 5%, while it was 38 ± 7% at both 5 and 10 years. The risk was significantly different in the three PA groups (Log Rank p = 0.033). PASE score was the only independent predictor of PCaR (HR: 0.987; 95%CI: 0.977–0.998; p = 0.016).

Conclusions

PA influences PCa evolution, as increasing levels are associated with a significantly reduced risk of tumor reclassification among patients undergoing active surveillance.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Kaplan-Meier analyses.

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30. https://doi.org/10.3322/caac.21590

    Article  PubMed  Google Scholar 

  2. Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65:1046–55. https://doi.org/10.1016/j.eururo.2013.12.062

    Article  PubMed  PubMed Central  Google Scholar 

  3. Bacon CG, Giovannucci E, Testa M, Glass TA, Kawachi I. The association of treatment-related symptoms with quality-of-life outcomes for localized prostate carcinoma patients. Cancer. 2002;94:862–71. https://doi.org/10.1002/cncr.10248

    Article  PubMed  Google Scholar 

  4. Cooperberg MR. Active surveillance for low-risk prostate cancer—an evolving international standard of care. JAMA Oncol. 2017;3:1398–9. https://doi.org/10.1001/jamaoncol.2016.3179

    Article  PubMed  Google Scholar 

  5. Klotz L. Active surveillance for low-risk prostate cancer. Curr Urol Rep. 2015;16:1–10. https://doi.org/10.1007/s11934-015-0492-z

    Article  Google Scholar 

  6. Sharma V, Wymer KM, Borah BJ, Barocas DA, Thompson RH, Karnes RJ, et al. Cost-effectiveness of active surveillance, radical prostatectomy and external beam radiotherapy for localized prostate cancer: an analysis of the protect trial. J Urol. 2019;202:964–72. https://doi.org/10.1097/JU.0000000000000345

    Article  PubMed  Google Scholar 

  7. Papadopoulos E, Alibhai SMH, Tomlinson GA, Matthew AG, Nesbitt M, Finelli A, et al. Influence of physical activity on active surveillance discontinuation in men with low-risk prostate cancer. Cancer Causes Control. 2019;30:1009–12. https://doi.org/10.1007/s10552-019-01211-0

    Article  PubMed  Google Scholar 

  8. Guy DE, Vandersluis A, Klotz LH, Fleshner N, Kiss A, Parker C, et al. Total energy expenditure and vigorous-intensity physical activity are associated with reduced odds of reclassification among men on active surveillance. Prostate Cancer Prostatic Dis. 2018;21:187–95. https://doi.org/10.1038/s41391-017-0010-0

    Article  PubMed  Google Scholar 

  9. Vandersluis AD, Guy DE, Klotz LH, Fleshner NE, Kiss A, Parker C, et al. The role of lifestyle characteristics on prostate cancer progression in two active surveillance cohorts. Prostate Cancer Prostatic Dis. 2016;19:305–10. https://doi.org/10.1038/pcan.2016.22

    Article  CAS  PubMed  Google Scholar 

  10. Ornish D, Weidner G, Fair WR, Marlin R, Pettengill EB, Raisin CJ, et al. Intensive lifestyle changes may affect the progression of prostate cancer. J Urol. 2005;174:1065–70. https://doi.org/10.1097/01.ju.0000169487.49018.73

    Article  PubMed  Google Scholar 

  11. Frattaroli J, Weidner G, Dnistrian AM, Kemp C, Daubenmier JJ, Marlin RO, et al. Clinical events in prostate cancer lifestyle trial: results from two years of follow-up. Urology. 2008;72:1319–23. https://doi.org/10.1016/j.urology.2008.04.050

    Article  PubMed  Google Scholar 

  12. van den Bergh RCN, Roemeling S, Roobol MJ, Roobol W, Schröder FH, Bangma CH. Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol. 2007;52:1560–3. https://doi.org/10.1016/j.eururo.2007.05.011

    Article  PubMed  Google Scholar 

  13. Washburn RA, Smith KW, Jette AM, Janney CA. The physical activity scale for the elderly (PASE): Development and evaluation. J Clin Epidemiol. 1993;46:153–62. https://doi.org/10.1016/0895-4356(93)90053-4

    Article  CAS  PubMed  Google Scholar 

  14. Wekesa A, Harrison M, Watson RW. Physical activity and its mechanistic effects on prostate cancer. Prostate Cancer Prostatic Dis. 2015;18:197–207. https://doi.org/10.1038/pcan.2015.9

    Article  CAS  PubMed  Google Scholar 

  15. Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol. 2011;29:726–32. https://doi.org/10.1200/JCO.2010.31.5226

    Article  PubMed  PubMed Central  Google Scholar 

  16. Van Blarigan EL, Gerstenberger JP, Kenfield SA, Giovannucci EL, Stampfer MJ, Jones LW, et al. Physical activity and prostate tumor vessel morphology: Data from the health professionals follow-up study. Cancer Prev Res. 2015;8:962–7. https://doi.org/10.1158/1940-6207.CAPR-15-0132

    Article  Google Scholar 

  17. Friedenreich CM, Wang Q, Neilson HK, Kopciuk KA, McGregor SE, Courneya KS. Physical activity and survival after prostate cancer. Eur Urol. 2016;70:576–85. https://doi.org/10.1016/j.eururo.2015.12.032

    Article  PubMed  Google Scholar 

  18. Wang Y, Jacobs EJ, Gapstur SM, Maliniak ML, Gansler T, McCullough ML, et al. Recreational physical activity in relation to prostate cancer-specific mortality among men with nonmetastatic prostate cancer. Eur Urol. 2017;72:931–9. https://doi.org/10.1016/j.eururo.2017.06.037

    Article  PubMed  Google Scholar 

  19. Bonn SE, Sjölander A, Lagerros YT, Wiklund F, Stattin P, Holmberg E, et al. Physical activity and survival among men diagnosed with prostate cancer. Cancer Epidemiol Biomark Prev. 2015;24:57–64. https://doi.org/10.1158/1055-9965.EPI-14-0707

    Article  CAS  Google Scholar 

  20. Ornish D, Lin J, Chan JM, Epel E, Kemp C, Weidner G, et al. Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study. Lancet Oncol. 2013;14:1112–20. https://doi.org/10.1016/S1470-2045(13)70366-8

    Article  CAS  PubMed  Google Scholar 

  21. Ornish D, Magbanua MJM, Weidner G, Weinberg V, Kemp C, Green C, et al. Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention. Proc Natl Acad Sci USA. 2008;105:8369–74. https://doi.org/10.1073/pnas.0803080105

    Article  PubMed  PubMed Central  Google Scholar 

  22. Magbanua MJM, Richman EL, Sosa EV, Jones LW, Simko J, Shinohara K, et al. Physical activity and prostate gene expression in men with low-risk prostate cancer. Cancer Causes Control. 2014;25:515–23. https://doi.org/10.1007/s10552-014-0354-x

    Article  PubMed  PubMed Central  Google Scholar 

  23. Schenk JM, Neuhouser ML, Beatty SJ, VanDoren M, Lin DW, Porter M, et al. Randomized trial evaluating the role of weight loss in overweight and obese men with early stage prostate cancer on active surveillance: rationale and design of the Prostate Cancer Active Lifestyle Study (PALS). Contemp Clin Trials. 2019;81:34–9. https://doi.org/10.1016/j.cct.2019.04.004

    Article  PubMed  PubMed Central  Google Scholar 

  24. De Nunzio C, Nacchia A, Cicione A, Cindolo L, Gacci M, Cancrini F, et al. Physical activity as a protective factor for lower urinary tract symptoms in male patients: a prospective cohort analysis. Urology. 2019;125:163–8. https://doi.org/10.1016/j.urology.2018.12.035

    Article  PubMed  Google Scholar 

  25. De Nunzio C, Presicce F, Lombardo R, Cancrini F, Petta S, Trucchi A, et al. Physical activity as a risk factor for prostate cancer diagnosis: a prospective biopsy cohort analysis. BJU Int. 2016;117:E29–35. https://doi.org/10.1111/bju.13157

    Article  CAS  PubMed  Google Scholar 

  26. De Nunzio C, Brassetti A, Proietti F, Deroma M, Esperto F, Tubaro A. Metabolic syndrome and smoking are associated with an increased risk of nocturia in male patients with benign prostatic enlargement. Prostate Cancer Prostatic Dis. 2018;21:287–92. https://doi.org/10.1038/s41391-017-0003-z

    Article  CAS  PubMed  Google Scholar 

  27. Peisch SF, Van Blarigan EL, Chan JM, Stampfer MJ, Kenfield SA. Prostate cancer progression and mortality: a review of diet and lifestyle factors. World J Urol. 2017;35:867–74. https://doi.org/10.1007/s00345-016-1914-3

    Article  CAS  PubMed  Google Scholar 

  28. Burton AJ, Martin RM, Donovan JL, Lane JA, Davis M, Hamdy FC, et al. Associations of lifestyle factors and anthropometric measures with repeat PSA levels during active surveillance/monitoring. Cancer Epidemiol Biomark Prev. 2012;21:1877–85. https://doi.org/10.1158/1055-9965. EPI-12-0411

    Article  CAS  Google Scholar 

  29. Salinas CA, Tsodikov A, Ishak-Howard M, Cooney KA. Prostate cancer in young men: an important clinical entity. Nat Rev Urol. 2014;11:317–23. https://doi.org/10.1038/nrurol.2014.91

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Brassetti A, Lombardo R, Emiliozzi P, Cardi A, Antonio DV, Antonio I, et al. Prostate-specific antigen density is a good predictor of upstaging and upgrading, according to the new grading system: the keys we are seeking may be already in our pocket. Urology. 2017;111:129–35. https://doi.org/10.1016/j.urology.2017.07.071

    Article  PubMed  Google Scholar 

  31. Leinwand GZ, Gabrielson AT, Krane LS, Silberstein JL. Rethinking active surveillance for prostate cancer in African American men. Transl Androl Urol. 2018;7:S397–410. https://doi.org/10.21037/tau.2018.06.19

    Article  PubMed  PubMed Central  Google Scholar 

  32. Welty CJ, Cowan JE, Nguyen H, Shinohara K, Perez N, Greene KL, et al. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. J Urol. 2015;193:807–11. https://doi.org/10.1016/j.juro.2014.09.094

    Article  PubMed  Google Scholar 

  33. De Nunzio C, Brassetti A, Simone G, Lombardo R, Mastroianni R, Collura D, et al. Metabolic syndrome increases the risk of upgrading and upstaging in patients with prostate cancer on biopsy: a radical prostatectomy multicenter cohort study. Prostate Cancer Prostatic Dis. 2018;21:438–45. https://doi.org/10.1038/s41391-018-0054-9

    Article  PubMed  Google Scholar 

  34. De Nunzio C, Simone G, Brassetti A, Mastroianni R, Collura D, Muto G, et al. Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: Results from a multicentre prospective study. BMC Cancer. 2016;16:407 https://doi.org/10.1186/s12885-016-2442-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Colicchia M, Morlacco A, Rangel LJ, Carlson RE, Dal Moro F, Karnes RJ, et al. Role of metabolic syndrome on perioperative and oncological outcomes at radical prostatectomy in a low-risk prostate cancer cohort potentially eligible for active surveillance. 2017. https://doi.org/10.1016/j.euf.2017.12.005

Download references

Author information

Authors and Affiliations

  1. Department of Urology, IRCCS “Regina Elena” National Cancer Institute, Rome, Italy

    Aldo Brassetti, Mariaconsiglia Ferriero, Gabriele Tuderti, Umberto Anceschi, Alfredo Bove, Leonardo Misuraca, Michele Gallucci & Giuseppe Simone

  2. Department of Urology, “Umberto I” Hospital, Nocera Inferiore, Italy

    Giorgio Napodano & Roberto Sanseverino

  3. Department of Urology, Istituto Nazionale Tumori di Milano, Milan, Italy

    Fabio Badenchini

  4. Department of Urology, “Sapienza” University of Rome, Rome, Italy

    Riccardo Mastroianni, Flavia Proietti & Michele Gallucci

Authors
  1. Aldo Brassetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mariaconsiglia Ferriero
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giorgio Napodano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roberto Sanseverino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fabio Badenchini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gabriele Tuderti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Umberto Anceschi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Alfredo Bove
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Leonardo Misuraca
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Riccardo Mastroianni
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Flavia Proietti
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Michele Gallucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Giuseppe Simone
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AB, MF, GN, RS, GT, UA, AB, LM, RM, and FP collected data while FB managed them. AB carried out statistical analysis and drafted the manuscript. MG and GS critically reviewed the paper. All authors have read and approved the final article.

Corresponding author

Correspondence to Aldo Brassetti.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Ethics approval and consent to participate

The retrospective study was performed in accordance with the Declaration of Helsinki. Review board approval was acquired; informed consent for the retrospective study was obtained from all the participants.

Informed consent

Informed consent for the submission and publication of the study was obtained from all individual participants included.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brassetti, A., Ferriero, M., Napodano, G. et al. Physical activity decreases the risk of cancer reclassification in patients on active surveillance: a multicenter retrospective study. Prostate Cancer Prostatic Dis 24, 1151–1157 (2021). https://doi.org/10.1038/s41391-021-00375-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41391-021-00375-8

This article is cited by

Search

Advanced search

Quick links